Quah S P, McBride M
Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast, UK.
Int J STD AIDS. 2001 Feb;12(2):126-7. doi: 10.1258/0956462011916776.
Improvement in the immunological and virological profile of HIV-infected population during the era of highly active antiretroviral therapy (HAART), has allowed guidelines on discontinuation of Pneumocystis carinii pneumonia (PCP) prophylaxis to be published. A case of a 37-year-old homosexual man, who had sustained CD4 count over 200 cells/microl for 2 years while on secondary prophylaxis for PCP, who then developed PCP after cessation of prophylaxis, is presented. This case emphasizes the need for close monitoring of patients who discontinued secondary PCP prophylaxis with respiratory symptoms.
在高效抗逆转录病毒治疗(HAART)时代,HIV 感染人群的免疫和病毒学状况有所改善,这使得关于停止卡氏肺孢子虫肺炎(PCP)预防治疗的指南得以发布。本文介绍了一名 37 岁同性恋男性的病例,该患者在接受 PCP 二级预防治疗期间,CD4 细胞计数持续超过 200 个/微升达 2 年,在预防治疗停止后发生了 PCP。该病例强调了对停止 PCP 二级预防治疗且出现呼吸道症状的患者进行密切监测的必要性。